Pulmonary-Allergy Drugs Panel Renewal

Federal Register notice: FDA has announced the renewal of the Pulmonary-Allergy Drugs Advisory Committee for an additional two years. The new charter will be in effect until 5/30/2020. To view the notice, click here.

Read more